000126752 001__ 126752
000126752 005__ 20241125101133.0
000126752 0247_ $$2doi$$a10.3390/cancers15112972
000126752 0248_ $$2sideral$$a134191
000126752 037__ $$aART-2023-134191
000126752 041__ $$aeng
000126752 100__ $$aIoakeim-Skoufa, Ignatios
000126752 245__ $$aDrug repurposing in oncology: a systematic review of randomized controlled clinical trials
000126752 260__ $$c2023
000126752 5060_ $$aAccess copy available to the general public$$fUnrestricted
000126752 5203_ $$aQuality pharmacological treatment can improve survival in many types of cancer. Drug repurposing offers advantages in comparison with traditional drug development procedures, reducing time and risk. This systematic review identified the most recent randomized controlled clinical trials that focus on drug repurposing in oncology. We found that only a few clinical trials were placebo-controlled or standard-of-care-alone-controlled. Metformin has been studied for potential use in various types of cancer, including prostate, lung, and pancreatic cancer. Other studies assessed the possible use of the antiparasitic agent mebendazole in colorectal cancer and of propranolol in multiple myeloma or, when combined with etodolac, in breast cancer. We were able to identify trials that study the potential use of known antineoplastics in other non-oncological conditions, such as imatinib for severe coronavirus disease in 2019 or a study protocol aiming to assess the possible repurposing of leuprolide for Alzheimer’s disease. Major limitations of these clinical trials were the small sample size, the high clinical heterogeneity of the participants regarding the stage of the neoplastic disease, and the lack of accounting for multimorbidity and other baseline clinical characteristics. Drug repurposing possibilities in oncology must be carefully examined with well-designed trials, considering factors that could influence prognosis.
000126752 536__ $$9info:eu-repo/grantAgreement/ES/DGA-FEDER/B01-20R$$9info:eu-repo/grantAgreement/ES/ISCIII-RICAPPS/RD21-0016-0019
000126752 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000126752 590__ $$a4.5$$b2023
000126752 592__ $$a1.391$$b2023
000126752 591__ $$aONCOLOGY$$b78 / 322 = 0.242$$c2023$$dQ1$$eT1
000126752 593__ $$aOncology$$c2023$$dQ1
000126752 593__ $$aCancer Research$$c2023$$dQ2
000126752 594__ $$a8.0$$b2023
000126752 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000126752 700__ $$aTobajas-Ramos, Natalia
000126752 700__ $$aMenditto, Enrica
000126752 700__ $$aAza-Pascual-Salcedo, Mercedes
000126752 700__ $$0(orcid)0000-0002-5440-1710$$aGimeno-Miguel, Antonio
000126752 700__ $$aOrlando, Valentina
000126752 700__ $$aGonzález-Rubio, Francisca
000126752 700__ $$0(orcid)0000-0001-8064-8138$$aFanlo-Villacampa, Ana$$uUniversidad de Zaragoza
000126752 700__ $$aLasala-Aza, Carmen
000126752 700__ $$aOstasz, Ewelina
000126752 700__ $$0(orcid)0000-0003-4629-6743$$aVicente-Romero, Jorge$$uUniversidad de Zaragoza
000126752 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000126752 773__ $$g15, 11 (2023), 2972$$pCancers$$tCancers$$x2072-6694
000126752 8564_ $$s1194258$$uhttps://zaguan.unizar.es/record/126752/files/texto_completo.pdf$$yVersión publicada
000126752 8564_ $$s2838001$$uhttps://zaguan.unizar.es/record/126752/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000126752 909CO $$ooai:zaguan.unizar.es:126752$$particulos$$pdriver
000126752 951__ $$a2024-11-22-11:59:32
000126752 980__ $$aARTICLE